Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Lumena Pharmaceuticals

- PMLiVE

Shire bags US approval for constipation drug Motegrity

Approval is boost as Takeda takeover nears completion

- PMLiVE

Roche gains EU PRIME status for Spinraza rival

Oral treatment joins Novartis' gene therapy challenger

- PMLiVE

NICE says no to rival Alnylam and Akcea amyliodsis drugs – but deal could be done

Room for manoeuvre after initial rejection

- PMLiVE

Biogen picks up another drug from wide-ranging Ionis alliance

Aims to follow success of Spinraza

- PMLiVE

Takeda secures investor backing for £46bn Shire takeover

The deal is expected to close early next year

- PMLiVE

Shire’s angioedema drug Takhzyro claims EU approval

Approval shortly follows a green light in the US

- PMLiVE

Orphan drugs from Biogen and Amicus win UK Prix Galien

New medical technology category added for the first time

- PMLiVE

Spinraza lifts Biogen ahead of Alzheimer’s data

Continued strong growth for Biogen’s spinal muscular atrophy therapy Spinraza helped the company exceed revenue expectations in the third quarter, but pipeline disappointments kept its shares largely static.Spinraza (nusinersen) was...

- PMLiVE

Shire’s angioedema drug Takhzyro recommended in Europe

Analysts expect the drug to make around $1.8bn in peak sales

- PMLiVE

Alnylam seeks fast-track filing with biomarker data

Early filing reflects FDA desire for faster approvals

- PMLiVE

Shire’s bleeding disorder drug approved in Europe

Veyvondi for patients with rare disease von Willebrand disease

- PMLiVE

Takeda rebels take aim at Shire acquisition

Shareholder group concerned about $30bn debt burden

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links